MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2026.2641340

Медицинская библиотека · The Journal of dermatological treatment · 2026

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.

Liu Jingjing, Shao Junyi, Hou Liyue, Mei Enci, He Lili, Wang Jingying, Chen Anqi, Zhang Yi, Li Zhiming

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

The efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.

OBJECTIVE

This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.

METHODS

This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included.

RESULTS

The proportions of patients achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static physician's global assessment (sPGA) 0/1 responses at week (W)12 were significantly higher in the vunakizumab group than in the placebo group, regardless of the duration of psoriasis, PASI score, body surface area (BSA) involvement, and sPGA score. Similarly, at W4 and W8, treatment response rates were higher in the vunakizumab group than in the placebo group, regardless of the above-mentioned features. The same trend was also found at W24. However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity.

CONCLUSION

Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity.

Для цитирования: Liu Jingjing, Shao Junyi, Hou Liyue, Mei Enci, He Lili, Wang Jingying, Chen Anqi, Zhang Yi, Li Zhiming. Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.. The Journal of dermatological treatment. 2026. DOI: 10.1080/09546634.2026.2641340.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.